Do you find our website to be helpful?
Yes   No

FLUENT Study Enrollment Closing — Act Now!

study

The FLUENT study will be closing enrollment at the end of the month, on June 30, 2018! Those diagnosed with Multiple Sclerosis (MS) who are interested in trying Gilenya (fingolimod) for the first time may be eligible to participate. The study simply asks for a few questionnaires and a blood draw at baseline and at the standard 1m, 3m, 6m, and 12m follow-up office visits to help learn more about how this medicine affects the immune system.

Neurology Advisor reports patients who have previously tried one or more injectable therapy (iDMTs) may still see improvement with a switch to a Gilenya pill once a day! Read it here.

Need more information? Check out this website or this one to learn more about these studies. 

If you or anyone you know are interested in learning more about this trial, feel free to call our Research Director, Lindsay, at 703-313-9111 ext. 107, or email her at Lindsay@integratedneurologyservices.com.

 

You Might Also Enjoy...

A new blood test to monitor multiple sclerosis

Currently, many neurologists do yearly MRIs to monitor multiple sclerosis disease activity. There is a new blood test that may monitor multiple sclerosis disease activity better in clinically stable patients.

Traumatic Brain Injury Dangers in the Winter

Winter sports are a fun and exhilarating way to enjoy the cold, snowy months. Gliding on ice, speeding down a hill, balancing on a board—it’s all quite exciting. But, high speeds and hard grounds can pose extra risks.